SLC22A8 and neoplasm: The results showed that the SLC22A8 low expression group had a higher immune score (Fig. 6F), stromal score (Fig. 6G), ESTIMATE score (Fig. 6H), and lower tumor purity (Fig. 6I) compared to the SLC22A8 high expression group.